Pharmaceutical Markets Biocon Strengthens its Presence in Mexico

Editor: Dominik Stephan

Biocon has announced that its Insulin Glargine has been approved by Cofepris, the Mexican health authority, through its partner Pisa Farmaceutica.

Related Vendors

(Picture: Michael Jarmoluk (CC0))

Bangalore/India; Mexico DF/Mexico - Mexico has been a very important market for Biocon since 2006, where it has been playing a significant role in enabling access to affordable rh-Insulin. Insulin Glargine will augment the affordable insulins therapy for diabetes management. ‘Galctus’ by Pisa is the first Insulin Glargine to be approved in Mexico as per the biocomparable approvals pathway defined in 2012.